Exercise-Triggered Hormone Changes in Men with Localized Prostate Cancer on Active Surveillance
Official title: Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer
Run by University of Miami · NCT07518888 · Data updated 2026-11-12
A short, home-based HIIT session is being tested to see if it temporarily changes steroid hormone levels in men with localized prostate cancer who are on active surveillance.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | Men only |
| Enrollment | 50 (estimated) |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Status | Recruiting |
| Started | November 30, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2029 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT07518888 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18-80 with localized prostate cancer currently on active surveillance and capable of performing moderate-to-high intensity exercise.
✕Probably not a fit
Patients with metastatic disease, undergoing treatment, or with medical contraindications to exercise may not experience benefit and may be unlikely to participate.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study looks at how a single session of bodyweight HIIT performed at home affects steroid hormone levels in men with localized prostate cancer on active surveillance. It is an interventional study conducted at the University of Miami with adult male participants who can engage in moderate-to-high intensity exercise. Participants perform a brief HIIT workout and researchers measure steroid-related hormones to understand hormonal responses. Eligible participants are English-speaking adults aged 18-80 without active cancer treatment or contraindicating medical conditions. Those who cannot consent or comply with requirements are excluded.
Why it matters
Potential benefit: If successful, the study could inform how exercise timing and intensity influence hormone profiles in men under active surveillance.
How similar studies have gone: Previous research suggests exercise can affect hormone levels, but this specific home-based HIIT approach in this population is relatively new.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males 18 to 80 years old * Diagnosis of localized prostate cancer * Currently under active surveillance * Ability to perform moderate-to-high intensity physical activity as demonstrated by self-assessment using the Physical Activity Readiness Questionnaire (PAR-Q+) * Able to independently perform activities of daily living, without limitations in mobility * Ability to read, write, speak, and understand English * Able and willing to sign consent and comply with study requirements Exclusion Criteria: * Males currently receiving treatment for prostate cancer * Diagnosis of metastatic prostate cancer * Individuals with medical conditions contraindicating exercise * Uncontrolled cardiovascular or circulatory diseases, hypertension, and diabetes, as determined by the study doctor or treating physician * Ongoing use of medications affecting steroid metabolism * Unable to sign consent and/or comply with study requirements
Where it's running
-
University of Miami Hospitals and Clinics
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Nima Sharifi, MD — University of Miami
- Study coordinator: Nima Sharifi, MD
- Email: nimasharifi@miami.edu
- Phone: 305-243-1350
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.